Misleading statements and lies from the 13d letter

New Post Public Reply Private Reply Replies (5) Message Board
ohm20
1,602
Misleading statements and lies from the 13d letter -

Quote:
Over the recent months, it has become clear that the Company has made virtually no progress in addressing the significant managerial and operational deficiencies that have destroyed stockholder value and led to unacceptable delays in receiving regulatory approval.


Correction to the BLA and submittal of justification letter. 2 Covid trials submitted to ANVISA with appropriate dosages and endpoints. Successful phase 2 longhaulers trial. NASH trial fully enrolled with results in 2020. Cancer trials completing enrollment with possible results 2020.

Quote:
In 2020, CYDY ran two clinical trials for Leronlimab, both of which were unsuccessful due to management’s and the board’s poor execution.


The 13d crew seem to be unaware that the FDA limited us to 2 doses. If they are that unaware woe to the shareholders if they take over.

Quote:
Dr. Pourhassan’s and Dr. Kelly’s tenures at CYDY have been marked by a consistent failure to meet FDA expectations leading to a poor and unsalvageable relationship.


The expectations from the FDA seem to be that Cytodyn will roll over and play dead. Why would anyone think this comes from management rather than other considerations held by FDA employees.

The FDA has done all in it's power to block approval for HIV. Insisting on a 700mg dose then making the company jump through hoops to prove it's the right dosage. Using the excuse of receptor occupancy when other HIV drugs have not been held to that standard and the correct predictor of dosage is safety and efficacy.

In CD12 a four dose regimen was requested and the FDA insisted on two. There was absolutely no reason for the FDA to insist on 2 doses in a 4 week trial.

Quote:
The FDA has repeatedly refused to authorize CYDY-led clinical trials or even authorize applications, putting the Company in an extremely precarious position from an operational and financial perspective.


The FDA has never refused a trial or leronlimab's use in any application. They screwed us on the protocol but the trial still went forward. Maybe they're thinking of Cytolin.

Quote:
Put simply, CYDY needs to restore its credibility with the FDA


Actions by the FDA in the last few years show it's the FDA that needs to restore it's own credibility.

Quote:
Dr. Pourhassan claimed that CYDY would be a three-digit share price company after the results of the CD12 trial were unpublished but known internally.


Doesn't 13d think that leronlimab will push Cytodyn into a triple digit stock? They must not be aware of the 65+ indications for leronlimab. Maybe they have a buyout waiting in the wings for a tiny price.

Quote:
This behavior, in part, led to an unusual public rebuke of CYDY by the FDA.


The FDA has been very specific that it was pushback from the public that resulted in the letter.

Quote:
CYDY has in the past boasted and issued news releases about collaborations with reputable research institutions and labs. These alleged collaborations included Drexel University, the Scripps Research Institute, and Georgetown Medical Center.


Drexel University trial was Withdrawn (Lack of enrollment) originally started under Progenics in 2011, Cytodyn pivoted to monotherapy. Georgetown University metastatic colorectal cancer trial substituted with cancer basket trial. Scripps pre-clinical study for PrEP unknown.

Quote:
Dr. Pourhassan made $9,971,254 in total compensation in 2020


This includes warrants and options exercised and sold many that were awarded earlier and he has held for years. Quite misleading and bandied about quite widely by those with an agenda.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 342

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading